SCHEDULE: StemPoint Capital Discloses 7.2% Stake in Xilio Therapeutics

StemPoint Capital LP, along with its affiliates, has reported a 7.2% beneficial ownership stake in Xilio Therapeutics, Inc., primarily through warrants.

Summary

• StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (the "Reporting Persons") jointly filed a Schedule 13G.
• The Reporting Persons beneficially own 4,000,000 shares of Xilio Therapeutics, Inc. Common Stock.
• This ownership represents 7.2% of the issuer's outstanding Common Stock.
• The 4,000,000 shares are acquirable through the exercise of pre-funded warrants for 2,000,000 shares and Class B warrants for 2,000,000 shares.
• The percentage of class is calculated based on 51,827,910 shares outstanding as of August 08, 2025, plus the shares to be acquired from the warrants.
• The Reporting Persons hold shared voting power and shared dispositive power over all 4,000,000 beneficially owned shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by an investment firm is generally a neutral to slightly positive signal, indicating an investor's confidence in the company's long-term prospects without implying active involvement in management or strategy.

Positives

• A significant beneficial ownership stake (7.2%) by an investment firm like StemPoint Capital can be viewed as a vote of confidence in Xilio Therapeutics, Inc.

Negatives

• NA

Risks

• NA

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding future performance or operations.

Industry Context

This filing indicates a significant passive investment by StemPoint Capital in Xilio Therapeutics, a biotechnology company. Such disclosures are common in the biotech sector where institutional investors often take positions based on pipeline potential or strategic developments.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may positively influence market perception and potentially the stock price, signaling external validation of the company's value.

Key Dates

Keywords

Xilio Therapeutics, StemPoint Capital, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Investment Adviser, Institutional Investor